

Attorney Docket No.: RTS-0335
Inventors: Kenneth W. Dobie
Serial No.: 10/006,972
Filing Date: December 4, 2001
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to nucleobases 1034 through 1635 of a 3'-untranslated region of a nucleic acid molecule encoding human phospholipid scramblase 3 (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding phospholipid scramblase 3 and inhibits the expression of phospholipid scramblase 3.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothic acid linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Attorney Docket No.: RTS-0335
Inventors: Kenneth W. Dobie
Serial No.: 10/006,972
Filing Date: December 4, 2001
Page 3

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claims 15-18 (canceled).

Claim 19 (original): The compound of claim 1 targeted to a nucleic acid molecule encoding phospholipid scramblase 3, wherein said compound specifically hybridizes with and differentially inhibits the expression of one of the variants of phospholipid

Attorney Docket No.: RTS-0335
Inventors: Kenneth W. Dobie
Serial No.: 10/006,972
Filing Date: December 4, 2001
Page 4

scramblase 3 relative to the remaining variants of phospholipid
scramblase 3.

Claim 20 (original): The compound of claim 19 targeted to a
nucleic acid molecule encoding phospholipid scramblase 3, wherein
said compound hybridizes with and specifically inhibits the
expression of a variant of phospholipid scramblase 3, wherein
said variant is selected from the group consisting of PLSCR3A,
PLSCR3B, PLSCR3C, PLSCR3D and PLSCR3E.

Claim 21 (new): The compound of Claim 1, wherein said
compound comprises at least an 8 nucleobase portion of SEQ ID
NO:59.

Claim 22 (new): The compound of claim 22, wherein said
compound comprises SEQ ID NO:59.

Claim 23(new): The compound of claim 22, wherein said
compound is SEQ ID NO:59.